1
|
Lewin A, McGowan E, Ou-Yang J, Boateng LA, Dinardo CL, Mandal S, Almozain N, Ribeiro J, Sasongko SL. The future of blood services amid a tight balance between the supply and demand of blood products: Perspectives from the ISBT Young Professional Council. Vox Sang 2024; 119:505-513. [PMID: 38272856 DOI: 10.1111/vox.13590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Revised: 12/07/2023] [Accepted: 12/29/2023] [Indexed: 01/27/2024]
Abstract
BACKGROUND AND OBJECTIVES Blood services manage the increasingly tight balance between the supply and demand of blood products, and their role in health research is expanding. This review explores the themes that may define the future of blood banking. MATERIALS AND METHODS We reviewed the PubMed database for articles on emerging/new blood-derived products and the utilization of blood donors in health research. RESULTS In high-income countries (HICs), blood services may consider offering these products: whole blood, cold-stored platelets, synthetic blood components, convalescent plasma, lyophilized plasma and cryopreserved/lyophilized platelets. Many low- and middle-income countries (LMICs) aim to establish a pool of volunteer, non-remunerated blood donors and wean themselves off family replacement donors; and many HICs are relaxing the deferral criteria targeting racial and sexual minorities. Blood services in HICs could achieve plasma self-sufficiency by building plasma-dedicated centres, in collaboration with the private sector. Lastly, blood services should expand their involvement in health research by establishing donor cohorts, conducting serosurveys, studying non-infectious diseases and participating in clinical trials. CONCLUSION This article provides a vision of the future for blood services. The introduction of some of these changes will be slower in LMICs, where addressing key operational challenges will likely be prioritized.
Collapse
Affiliation(s)
- Antoine Lewin
- Medical Affairs and Innovation, Héma-Québec, Montreal, Quebec, Canada
- Medicine faculty and health science, Sherbrooke University, Sherbrooke, Quebec, Canada
| | - Eunike McGowan
- Research and Development, Australian Red Cross Lifeblood, Brisbane, Australia
- Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, Lund, Sweden
| | | | - Lilian Antwi Boateng
- Department of Medical Diagnostics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
- Immunohaematology laboratory, University Health Services, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
| | | | - Saikat Mandal
- Medical Oncology, Hull York Medical School, University of Hull, Hull, UK
| | - Nour Almozain
- Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia
- Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| | - Jannison Ribeiro
- Centro de Hematologia e Hemoterapia do Ceará - Hemoce, Fortaleza, Brazil
- Instituto Pró-Hemo Saúde - IPH, Fortaleza, Brazil
| | - Syeldy Langi Sasongko
- Department of Public and Occupational Health, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands
| |
Collapse
|
2
|
De Silvestro G, Gandini G, Fiorin F, Marson P, Barbone E, Frigato A, Gessoni G, Veronesi A, Pacenti M, Castelli M, Rinaldi M, Rizzi M, Stefani F, Roveroni G. Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies. Transfus Apher Sci 2021; 60:103154. [PMID: 33994107 PMCID: PMC8103741 DOI: 10.1016/j.transci.2021.103154] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 04/27/2021] [Accepted: 04/30/2021] [Indexed: 02/02/2023]
Abstract
Background Convalescent plasma (CP) has been used in the past in various pandemics, in particular in H1N1, SARS and MERS infections. In Spring 2020, when ongoing the SARS-CoV-2 pandemics, the Veneto Region (V-R) has proposed setting-up an anti-SARS-CoV-2 CP (CCP) Bank, with the aim of preparing a supply of CCP immediately available in case of subsequest epidemic waves. Materials and Methods Key-points to be developed for a quick set-up of the V-R CCP Bank have been recruitment of donors recovered from COVID-19 infection, laboratory analysis for the biological qualification of the CCP units, including titre of neutralizing antibodies and reduction of pathogens, according to National Blood Centre (CNS) Directives, adaptation of the V-R Information Technology systems and cost analysis. Some activities, including diagnostic and viral inactivation processes, have been centralized in 2 or 3 sites. Laboratory analysis upon preliminary admission of the donor included all tests required by the Italian laws and the CNS directives. Results From April to August 2020, 3,298 people have contacted the V-R Blood Transfusion Services: of these, 1,632 have been evaluated and examined as first time donors and those found to be suitable have carried out 955 donations, from which 2,626 therapeutic fractions have been obtained, at a cost around 215,00 Euro. Since October 2020, the number of COVID-19 inpatients has had a surge with a heavy hospital overload. Moreover, the high request of CCP therapy by clinicians has been just as unexpected, showing a wide therapeutic use. Conclusions The organizational model here presented, which has allowed the rapid collection of a large amount of CCP, could be useful when facing new pandemic outbreaks, especially in low and middle income countries, with generally acceptable costs.
Collapse
Affiliation(s)
| | - Giorgio Gandini
- Transfusion Medicine Department of Verona, University Hospital of Verona, Italy
| | - Francesco Fiorin
- Transfusion Medicine Department of Vicenza, San Bortolo Hospital of Vicenza, Italy
| | - Piero Marson
- Transfusion Medicine Department of Padova, University Hospital of Padova, Italy
| | - Ersilia Barbone
- Transfusion Medicine Department of Belluno, San Martino Hospital of Belluno, Italy
| | - Andrea Frigato
- Transfusion Medicine Department of Rovigo, S. Maria della Misericordia Hospital of Rovigo, Italy
| | - Gianluca Gessoni
- Transfusion Medicine Department of Venezia, Dell'Angelo Hospital of Mestre (Venice), Italy
| | - Arianna Veronesi
- Transfusion Medicine Department of Treviso, Ca' Foncello Hospital of Treviso, Italy
| | - Monia Pacenti
- Institute of Microbiology and Virology, University Hospital of Padova, Italy
| | - Monica Castelli
- Transfusion Medicine Department of Vicenza, San Bortolo Hospital of Vicenza, Italy
| | - Marianna Rinaldi
- Transfusion Medicine Department of Verona, University Hospital of Verona, Italy
| | - Monica Rizzi
- Transfusion Medicine Department of Verona, University Hospital of Verona, Italy
| | - Francesca Stefani
- Transfusion Medicine Department of Vicenza, San Bortolo Hospital of Vicenza, Italy
| | | |
Collapse
|
3
|
Dhiman Y, Coshic P, Pandey HC, Khatiwada B, Singh J, Mehta V, Gupta S. Deterrents in recruitment of COVID-19 convalescent plasma donors: Experience from a hospital-based blood centre in India. Transfus Med 2021; 31:149-154. [PMID: 33749020 PMCID: PMC8251325 DOI: 10.1111/tme.12768] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Revised: 02/19/2021] [Accepted: 02/25/2021] [Indexed: 12/16/2022]
Abstract
INTRODUCTION Recruitment of Covid-19 convalescent plasma (CCP) donors may present as a challenge due to inexperience and differences in donor profile as compared to whole blood donation. Present study highlights the deterrents to recruiting CCP donors at a hospital based blood centre. MATERIALS AND METHODS Potential CCP donors were contacted individually by telephone and a group approach through camp organisers from May to July 2020. Recruitment challenges were noted and deferrals of these recruited donors during screening and medical examination was obtained and analysed. RESULTS Total 1165 potential CCP donors were contacted. Around 47% donors were lost due to challenges related to information storage and retrieval. Fear of health, family pressure, and fear of a new procedure were major reason (27.2%) for unwillingness to donate. The main reasons for deferral among potential donors were multiparity (38%) and being overage/underage (31.6%). Finally, 468 donors were recruited including 408 by individual approach and 60 by a group approach. From these absence of detectable COVID-19 antibodies were found in 15.4%. Few donors (9.0%) were deferred as they had not completed 28 days post recovery. CONCLUSION The process of CCP donor recruitment differs from that of whole blood donation and requires an individualised approach with involvement of clinicians in the initial phases of the pandemic. A group approach targeting specific organisations could be adopted for a successful CCP collection program. There is a need to relook into some aspects of donor selection such as consideration of multiparous female donors and overage/underage donors after reviewing scientific evidence.
Collapse
Affiliation(s)
| | - Poonam Coshic
- Department of Transfusion Medicine, AIIMS, New Delhi, India
| | | | | | - Jasmeet Singh
- Department of Transfusion Medicine, AIIMS, New Delhi, India
| | - Vikas Mehta
- Department of Transfusion Medicine, AIIMS, New Delhi, India
| | - Sanjay Gupta
- Department of Transfusion Medicine, AIIMS, New Delhi, India
| |
Collapse
|
4
|
Ripoll JG, van Helmond N, Senefeld JW, Wiggins CC, Klassen SA, Baker SE, Larson KF, Murphy BM, Andersen KJ, Ford SK, Casadevall A, Joyner MJ. Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19. Clin Microbiol Newsl 2021; 43:23-32. [PMID: 33564204 PMCID: PMC7862032 DOI: 10.1016/j.clinmicnews.2021.02.001] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Convalescent plasma has emerged as a promising therapeutic agent for patients with coronavirus disease 2019 (COVID-19), has received emergency use authorization, and is being widely used during the COVID-19 pandemic. Passive antibody therapy via plasma or serum has been successfully used to treat infectious diseases for more than a century. Passive antibody administration is based on the presumption that convalescent plasma or serum contains therapeutic antibodies that can be passively transferred to the plasma recipient. There are numerous examples in which convalescent plasma has been used successfully as post-exposure prophylaxis and treatment of infectious diseases, including previous coronavirus outbreaks. In the context of the COVID-19 pandemic, convalescent plasma was demonstrated to be safe and potentially effective among patients infected with COVID-19. This review provides an overview of the historical uses of convalescent plasma therapy, summarizes current evidence for convalescent plasma use for COVID-19, and highlights future antibody therapies.
Collapse
Affiliation(s)
- Juan G Ripoll
- Department of Anesthesiology, and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
| | - Noud van Helmond
- Department of Anesthesiology, Cooper Medical School of Rowan University, Cooper University Health Care, Camden, New Jersey
| | - Jonathon W Senefeld
- Department of Anesthesiology, and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
| | - Chad C Wiggins
- Department of Anesthesiology, and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
| | - Stephen A Klassen
- Department of Anesthesiology, and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
| | - Sarah E Baker
- Department of Anesthesiology, and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
| | - Kathryn F Larson
- Department of Anesthesiology, and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota
| | - Brenna M Murphy
- Department of Anesthesiology, and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
| | - Kylie J Andersen
- Department of Anesthesiology, and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
| | - Shane K Ford
- Department of Anesthesiology, and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
| | - Arturo Casadevall
- Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
| | - Michael J Joyner
- Department of Anesthesiology, and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota
| |
Collapse
|